FDA Approves OTC Naloxone Nasal Spray RiVive For Opioid Overdose

The U.S. Food and Drug Administration approved Harm Reduction Therapeutics' RiVive, 3 milligram naloxone hydrochloride nasal spray for over-the-counter or OTC, nonprescription use for the emergency treatment of known or suspected opioid overdose. The agency's second nonprescription naloxone product approval is expected to help increase consumer access to naloxone without a prescription.

from RTT - Top Story https://ift.tt/1mHA7tj
via IFTTT